Jolly Good/Teijin Pharma develop VR digital therapeutics for depression
pharmaphorum
APRIL 26, 2021
Technology firm Jolly Good and Teijin Pharma have begun a partnership to develop virtual reality digital therapeutics (VR DTx) for major depressive disorder. It also develops services to support the evolution of medical care and finding purposes in life, in collaboration with various research institutions and companies.
Let's personalize your content